Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Should Japan Go Ahead with Off-Year Re-Pricing amid COVID-19 Outbreak? Chuikyo Members Want It Discussed
Members of an all-important reimbursement policy panel on April 8 called for discussions on whether Japan should go ahead with its plan to implement so-called “off-year” re-pricing from next April despite the current unusual circumstances surrounding the novel coronavirus pandemic.…
To read the full story
Related Article
- Industry Says There’s No Way Off-Year Drug Price Survey Can Be Done; Chuikyo Healthcare Reps Agree but Payers Don’t
June 11, 2020
- Chuikyo Wary about Off-Year Price Survey amid COVID-19, Industry Officials Stress Concerns
May 28, 2020
- Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
April 27, 2020
- Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
REGULATORY
- MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
- Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…